Endometriosis Biomarkers Could Explain the Pain Gap

Endometriosis biomarkers could eventually help explain one of the condition’s most persistent clinical puzzles: why pain severity often bears little relationship to how extensive the visible disease appears. Some women have severe pelvic pain with relatively few lesions, while others have widespread disease and few or no symptoms.

A small 2026 tissue study now points toward biological differences between painful and pain-free disease. Alongside emerging research in exercise physiology and spaceflight, it also illustrates a broader principle of biomarker science: a measurable signal is useful only when researchers understand what it represents, where it was measured and how closely it tracks the outcome that matters.

Endometriosis biomarkers reveal different inflammatory activity

Published in Molecular Human Reproduction, the endometriosis study compared gene expression in peritoneal biopsy samples from nine symptomatic and ten asymptomatic participants. Researchers performed RNA sequencing on 27 preserved tissue samples and identified 890 genes with different expression between the two groups.

Many of the strongest signals were associated with inflammatory signalling, immune pathways, cell adhesion and neuromodulation. The inflammatory candidates included IL16, IL17RA and JAK3, while other differences involved genes potentially relevant to how cells attach or how nerve-related signalling is regulated. Pathway analysis found 22 enriched biological pathways, seven of them immunological.

This was a small, observational tissue study. It found associations rather than proving that any individual gene causes pelvic pain. The samples were also taken from lesions, not from blood or another easily collected material. These findings therefore do not amount to a new diagnostic blood test, nor do they establish a treatment target ready for routine care.

Even so, the comparison matters. It suggests that symptomatic and asymptomatic endometriosis may differ at a molecular level despite sharing the same broad diagnosis. Pain could reflect local immune and nerve biology that conventional disease staging does not adequately capture.

Why visible disease is an incomplete pain biomarker

Current endometriosis assessment often includes symptoms, imaging and, in some circumstances, surgery. Yet lesion burden is an imperfect proxy for the lived severity of the condition. The new gene-expression study provides a plausible biological reason: lesions may not all be equally inflammatory or equally capable of interacting with pain pathways.

That distinction is important when interpreting a scan or surgical stage. A lower apparent burden should not be treated as evidence that severe pain is disproportionate or unexplained. Conversely, extensive disease does not guarantee pain. Biomarkers must be validated against clinically meaningful outcomes, rather than assumed to matter because they are visible or technically measurable.

The same caution applies to symptom data. Pelvic pain varies with bleeding, sleep, digestion, stress, medication and cycle phase. None of those factors makes the pain less biological. They can influence inflammatory activity, pain processing or the ability to recover from a flare. A structured perimenopause symptom tracker can also be useful later in reproductive life, when changing cycles and overlapping symptoms may make patterns harder to separate.

Biomarkers need context, timing and repeated measurement

Two other recent studies demonstrate why isolated measurements can mislead. In a randomised, double-blind trial published in Medicine & Science in Sports & Exercise, 12 healthy young adults, including four females, received caffeine or placebo before repeated sprint testing. Caffeine improved mean sprint power across sets during a protocol lasting 3.5 hours. Researchers also measured plasma caffeine and noradrenaline, heart rate, breathing, perceived exertion, muscle pain and blood-flow indicators.

The design was stronger for testing short-term causality than an observational study, but the sample was very small and included only four females. It cannot establish whether menstrual phase, hormonal contraception or menopausal status modifies caffeine metabolism, cardiovascular responses or perceived effort. It does show how a biomarker’s meaning changes with timing. A caffeine concentration, heart-rate value or exertion score taken without knowing dose and time since ingestion offers limited information.

A longitudinal metabolomics study in Nature Communications examined spaceflight and reported increased gut microbial protein fermentation as intestinal transit slowed. Although the supplied material does not report the sample size or sex breakdown, its repeated-measure design highlights another core issue: biological values respond to environment, movement, diet and altered routine. The findings are highly specialised and cannot be directly applied to everyday constipation, but they show why a single metabolite reading is not a complete account of gut function.

Across these studies, context turns measurements into interpretable evidence. Relevant context may include cycle day, caffeine dose, recent exercise, bowel transit, sleep and medication exposure. Without it, even a precise laboratory result can be biologically ambiguous.

What would make a useful endometriosis test

A clinically useful endometriosis biomarker would need to perform reliably in larger and more diverse populations. Researchers would have to determine whether it distinguishes endometriosis from other causes of pelvic pain, whether it changes across the menstrual cycle and whether treatments alter the signal. Ideally, it would be measurable through a practical sample such as blood, urine or menstrual fluid, but convenience alone would not make it valid.

Pain-related markers may ultimately serve a different purpose from markers of disease presence or lesion burden. One test might support diagnosis, another could indicate inflammatory activity, and a third might help predict response to a specific treatment. Combining molecular measures with symptom trajectories may prove more informative than searching for one universal number.

There is also a risk of overpromising precision. The new findings concern gene activity within sampled tissue and require replication. They should not be interpreted as evidence that an inflammatory supplement, restrictive diet or consumer test can identify or treat the molecular pattern described. Biomarker discovery is the opening stage of a long validation process.

Symptom patterns remain clinically meaningful data

Until validated molecular tests become available, repeated observations of pain timing and associated symptoms remain useful. Cycle day, bleeding, bowel changes, sleep disruption, energy and recovery can help distinguish persistent patterns from isolated bad days and provide richer context for clinical conversations. Guidance on how perimenopause tracking works can be relevant when pelvic symptoms begin changing alongside cycle length or bleeding patterns.

Pelvic pain and related cycle symptoms only become readable as patterns when they are logged consistently over weeks. This is the kind of pattern Tulsy is built to surface.

Sources: Medical Xpress, ScienceDaily.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.